Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday, after the health-care company reported first-quarter earnings that beat expectations, sales that were slightly above and full-year profit guidance that was in line. Net income rose to $1.13 billion, or 38 cents a share, from $1.05 billion, or 23 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS rose to 63 cents from 59 cents, above the FactSet consensus of 61 cents. Sales increased 2% to $7.54 billion, topping the FactSet consensus of $7.48 billion. Medical device sales rose 5.5% to $2.90 billion, above the FactSet consensus of $2.88 billion; diagnostic sales edged up 0.2% to $1.84 billion, matching expectations; nutrition sales grew 2.0% to $1.79 billion versus expectations of $1.74 billion; and established pharmaceutical sales fell 4.9% to $992 million, missing expectations of $999.4 million. The company expects adjusted EPS of 79 cents for the second-quarter, surrounding the FactSet consensus of 80 cents, and $3.15 to $3.25 for 2019, compared with expectations of $3.21. The stock has tacked on 5.6% year to date through Tuesday, while the S&P 500 has rallied 16%.